ResearchMoz

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth

GBI Research
Published Date » 2014-02-06
No. Of Pages » 76
   
 GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth.” The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.  
   
 Cystic Fibrosis Transmembrane conductance...
TABLE OF CONTENT

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis
2.7 Assessment of Disease Severity
2.8 Treatment

3 Marketed Products
3.1 Overview
3.2 Product Profiles
3.2.1 Pulmozyme (dornase alfa) – Genentech
3.2.2 Bronchitol (mannitol) – Pharmaxis
3.2.3 TOBI (tobramycin) – Novartis
3.2.4 TOBI Podhaler (tobramycin) – Novartis
3.2.5 Bramitob/Bethkis (tobramycin) – Chiesi Farmaceutici
3.2.6 Colobreathe (colistimethate sodium) – Forest Laboratories
3.2.7 Cayston (aztreonam) – Gilead Sciences
3.2.8 Kalydeco (ivacaftor) – Vertex Pharmaceuticals
3.2.9 Pancreatic Enzyme Replacement Therapies
3.2.10 Other Successful Products
3.3 Heat Map of Marketed Products
3.4 Conclusion

4 Developmental Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.4 Promising Pipeline Molecules
4.4.1 Lumacaftor (VX809) – Vertex Pharmaceuticals
4.4.2 Ataluren (PTC124) – PTC Therapeutics
4.4.3 Aeroquin (levofloxacin) – Aptalis Pharma
4.4.4 Arikace (amikacin liposomal) – Insmed
4.4.5 Other Promising Molecules
4.5 Heat Map of Pipeline Products
4.6 Conclusion

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Markets
5.1.2 North America
5.1.3 Top Five EU Countries
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Co-Development Deals
6.2 Major Licensing Deals

7 Appendix
7.1 References
7.1.1 Marketed Product Heat Map References
7.1.2 Pipeline Product Heat Map References
7.2 Market Definition
7.3 Abbreviations
7.4 Methodology
7.5 Coverage
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Geographical Landscape
7.11 Pipeline Analysis
7.12 Competitive Landscape
7.12.1 Expert Panel Validation
7.13 Contact Us
7.14 Disclaimer

List of Tables


Table 1: Cystic Fibrosis Market, Global, Treatment Plan
Table 2: Cystic Fibrosis Market, Global, Pipeline, Preclinical
Table 3: Cystic Fibrosis Market, Global, Pipeline, Phase I
Table 4: Cystic Fibrosis Market, Global, Pipeline, Phase II
Table 5: Cystic Fibrosis Market, Global, Pipeline, Phase III
Table 6: Cystic Fibrosis Market, Global, Pipeline, Pre-Registration
Table 7: Cystic Fibrosis Market, Global, Pipeline, Undisclosed
Table 8: Cystic Fibrosis Market, Global, Market Forecast, 2012-2019
Table 9: Cystic Fibrosis Market, US, Market Forecast, 2012-2019
Table 10: Cystic Fibrosis Market, Canada, Market Forecast, 2012-2019
Table 11: Cystic Fibrosis Market, UK, Market Forecast, 2012-2019
Table 12: Cystic Fibrosis Market, France, Market Forecast, 2012-2019
Table 13: Cystic Fibrosis Market, Germany, Market Forecast, 2012-2019
Table 14: Cystic Fibrosis Market, Italy, Market Forecast, 2012-2019
Table 15: Cystic Fibrosis Market, Spain, Market Forecast, 2012-2019

List of Figures


Figure 1: Cystic Fibrosis Market, Global, Marketed, Heat Map
Figure 2: Cystic Fibrosis Market, Global, Pipeline Summary
Figure 3: Cystic Fibrosis Market, Global, Pipeline Mechanisms of Action
Figure 4: Cystic Fibrosis Market, Global, Clinical Trial Failure Rate
Figure 5: Cystic Fibrosis Market, Global, Pipeline Trial Duration
Figure 6: Cystic Fibrosis Market, Global, Pipeline, Trial Duration by Mechanism of Action
Figure 7: Cystic Fibrosis Market, Global, Pipeline Trial Size
Figure 8: Cystic Fibrosis Market, Global, Pipeline, Trial Size by Mechanism of Action
Figure 9: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Lumacaftor Forecast,
2015-2019
Figure 10: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Ataluren Forecast,
2016-2019
Figure 11: Cystic Fibrosis Market, Global, Pipeline Promising Pipeline Products, Aeroquin Forecast,
2014-2019
Figure 12: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Arikace Forecast,
2015-2019
Figure 13: Cystic Fibrosis Market, Global, Pipeline, Heat Map
Figure 14: Cystic Fibrosis Market, Global, Treatment Patterns, 2012–2019
Figure 15: Cystic Fibrosis Market, Global, Market Size, 2012–2019
Figure 16: Cystic Fibrosis Market, North America, Treatment Patterns, 2012–2019
Figure 17: Cystic Fibrosis Market, North America, Annual Cost of Treatment, 2012–2019
Figure 18: Cystic Fibrosis Market, North America, Market Size, 2012–2019
Figure 19: Cystic Fibrosis Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 20: Cystic Fibrosis Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 21: Cystic Fibrosis Market, Top Five EU Countries, Market Size, 2012–2019
Figure 22: Cystic Fibrosis Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 23: Cystic Fibrosis Market, Global, Major Co-development Deals by Year, 2006–2013
Figure 24: Cystic Fibrosis Market, Global, Co-development Deals by Phase, 2006–2013
Figure 25: Cystic Fibrosis Market, Global, Licensing Deals by Region, 2006–2013
Figure 26: Cystic Fibrosis Market, Global, Licensing Deals by Year, 2006–2013
Figure 27: Cystic Fibrosis Market, Global, Licensing Deals by Phase, 2006–2013
Figure 28: Forecasting Model for Therapeutic Areas

Upcoming Reports:

Plastic Polymers Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
The research and development over the plastic material led to the invention of Polymer Plastics which is a long chain of different but similar categorical molecules or a combination of many units.  The plastic polymers are of the following two types: Thermoplastic polymers Thermoset polymers The thermoplastic polymers can be heated and reheated again and again possessing  a unique capability which is quite useful in manufacturing new articles or components of different products.  The invention of plastic created a new...
Early Toxicity Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Toxicity is an extent to which a particular substance can damage the living organism; it is important parameter to be evaluated during all stages of drug development. Toxicity is one of the major reasons for failure of drug development and rejection of drug candidate. Toxicity can be because of dosage, form, half life and other parameters of drug. Since long time toxicity is measured at the later stage of the drug development process but considering higher rejection rate of drug in recent years citing high toxicity level and cost impact of later stage failure, companies...
Portable Power Fuel Cell Market - Global Industry size, market share, trends, analysis and forecasts 2012 - 2018
By - Transparency Market Research
Portable power fuel cell market is witnessing significant growth since past few years due to its use in number of applications. With advancement in science and technology, there emerged a need for portable electrical energy source which has given rise to development of portable power fuel cells. Fuel cells are more energy efficient and it is believed that traditional batteries will not provide required energy for the modern age electronic devices. Hence, such portable power fuel cells are best alternative for batteries.   Increasing adoption of portable fuel cells is...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Paracetamol doesn’t speed recovery or reduce low back pain: Study
Jul 24, 2014  
Paracetamol, which has long since been prescribed as a painkiller for severe low back pain, is no better than placebo; findings of a recent study in Australia have shown. The trial that was published on Thursday found that the universally recommended painkiller neither speeds recovery nor reduces the pain. Paracetamol is merely acts as a placebo or dummy pills doing nothing to ease the...
New Zealand feeds Asian hunger for food and beverages
Jul 24, 2014  
A report published by New Zealand Government, ‘What does Asia Want for Dinner? Emerging Market Opportunities for New Zealand food & beverages in East & South East Asia’, states that the whole of Asian food and beverages market have been a great driving force for New Zealand (NZ). This demand has expanded New Zealand’s scope for diversification and helped in its...